Why has the Pro Medicus share price surged 32% in a month?

Recent contract wins are improving the company's earnings outlook.

Key points
  • The Pro Medicus share price has been rising over the past month
  • The company has recently won contract renewals at a higher fee per transaction
  • The business has a very high EBIT margin

The Pro Medicus Limited (ASX: PME) share price has been surging higher in recent weeks. It closed 5.7% higher at $51.17 on Thursday and is now up 32% in a month.

This year has been a volatile one for the ASX healthcare share. It climbed above $66 earlier in the year before falling below $38 in mid-June. But it has been going upwards since then.

The company may have partly gone up as part of a broader recovery along with many other ASX growth shares. For example, the Xero Limited (ASX: XRO) share price has risen 18% over the past month and the REA Group Limited (ASX: REA) share price has soared by around 23%. The S&P/ASX 200 Index (ASX: XJO) is up by more than 4% over the same timeframe.

But, the rise that Pro Medicus has experienced only recovers some of the lost ground — the current price represents a fall of around 19% this year to date.

Two happy scientists analysing test results in a lab

Image source: Getty Images

Contract wins

Pro Medicus announced in mid-June that its Visage Imaging business had signed two contract renewals with a combined minimum value of $47 million. These two were Sutter Health, which renewed for seven years, and Wellspan Health, which renewed for five.

The contract renewals are transaction-based with committed minimums with potential upside.

For me, and perhaps investors, a key element from the update was that the renewals were negotiated at an increased fee per transaction compared to the original contracts.

Pro Medicus CEO Dr Sam Hupert explained why this update was so positive:

The industry norm for renewals is for short extensions to the original contract at the same or lower price. The fact that our clients have renewed for a full or longer contract term at an increased price supports our belief that the Visage solution delivers unparalleled value both in terms of financial and clinical ROI (return on investment).

Whilst it is still early days, our renewal success rate sends a positive message to the market and helps build on the network effect that we have been experiencing.

Extremely profitably

Pro Medicus has one of the highest earnings before interest and tax (EBIT) margins on the ASX. In the FY22 half-year result, the EBIT margin was 65%. This helped net profit after tax (NPAT) grow by 52.7% to $20.7 million, which then funded a 42.9% rise of the interim dividend to 10 cents per share.

Any new revenue that the company generates is being turned into profit at a high rate. Therefore, contract wins and contract renewals (with a higher fee per transaction) can help Pro Medicus' profit. Rising profit can be an important factor for pushing the Pro Medicus share price higher.

Pro Medicus share snapshot

Despite its recent gains, the Pro Medicus share price remains 12% over the past 12 months.

At the current share price, the company has a market capitalisation of $5 billion, according to the ASX.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus Ltd. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »